SLFN5 (schlafen family member 5) is an interferon-inducible protein that plays multifaceted roles in cell cycle regulation, cellular differentiation, and tumor biology. SLFN5 functions as a critical regulator of cell cycle progression, with expression peaking during S phase and interacting with protein phosphatase 2A to control mitotic entry and meiotic resumption 1. The protein acts as a host defense mechanism by inhibiting LINE-1 retrotransposition through binding to LINE-1 RNA and disrupting ribonucleoprotein particle formation via its helicase domain 2. In cancer contexts, SLFN5 exhibits tumor-suppressive properties in renal cell carcinoma by negatively regulating matrix metalloproteinase expression and reducing cell motility and invasiveness, with higher expression correlating with better patient survival 3. Conversely, in glioblastoma, SLFN5 promotes malignancy by acting as a transcriptional co-repressor of STAT1-mediated interferon responses, creating a negative feedback loop that suppresses antitumor immune responses 4. Additionally, SLFN5 expression is suppressed by histone H4K12 lactylation in triple-negative breast cancer, contributing to tumor progression 5, and its regulation affects diabetic wound healing through the PI3K/Akt/NRF2 pathway 6.